Course of murine tuberculosis and response to first-line therapy depends on route of infection and inoculum size

International Journal of Tuberculosis and Lung Disease

Volumn 15, Issue 11, 2011, Pages 1478-1484

  De Steenwinkel, Jurriaan E M ^a   Ten Kate, M T ^a   De Knegt, G J ^a   Verbrugh, H A ^a   Van Belkum, A ^a   Hernandez Pando, R ^b   Bakker Woudenberg, I A J M ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

Author keywords

Animal model; Route of infection; Tuberculosis

Indexed keywords

ISONIAZID; PYRAZINAMIDE; RIFAMPICIN; TUBERCULOSTATIC AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL LOAD; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; FEMALE; HISTOPATHOLOGY; INOCULATION; INTERMETHOD COMPARISON; MOLECULAR PATHOLOGY; MOUSE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RELAPSE; TUBERCULOSIS; TUBERCULOSIS CONTROL;

ANIMALS; ANTITUBERCULAR AGENTS; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; FEMALE; INHALATION EXPOSURE; INJECTIONS, INTRAVENOUS; LIVER; LUNG; MICE; MICE, INBRED BALB C; MYCOBACTERIUM TUBERCULOSIS; RECURRENCE; REPRODUCIBILITY OF RESULTS; SPLEEN; TIME FACTORS; TUBERCULOSIS; TUBERCULOSIS, PULMONARY;

EID: 80053972438     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: 10.5588/ijtld.11.0012     Document Type: Article

References (17)

1. World Health Organization. Global tuberculosis control 2009: epidemiology, strategy and financing. WHO/HTM/TB/2009. 411. Geneva, Switzerland: WHO, 2009: 1-314.
2. Palomino J C, Ramos D F, da Silva P A. New anti-tuberculosis drugs: strategies, sources and new molecules. Curr Med Chem 2009; 16: 1898-1904.
3. Bakker-Woudenberg I A. Experimental models of pulmonary infection. J Microbiol Methods 2003; 54: 295-313. (Pubitemid 36773973)
4. De Steenwinkel J E, De Knegt G J, Ten Kate M T, et al. Immunological parameters to define infection progression and therapy response in a well-defined tuberculosis model in mice. Int J Immunopathol Pharmacol 2009; 22: 723-734.
5. Blumberg H M, Burman W J, Chaisson R E, et al. American Thoracic Society/Centers for Disease Control and Prevention/ Infectious Diseases Society of America: treatment of tuberculosis. Am J Respir Crit Care Med 2003; 167: 603-662.
6. Stop TB Partnership and World Health Organization. Global Plan to Stop TB 2006-2015. Geneva, Switzerland: WHO, 2006: 1-172.
7. Lalande V, Truffot-Pernot C, Paccaly-Moulin A, et al. Powerful bactericidal activity of sparfloxacin (AT-4140) against Mycobacterium tuberculosis in mice. Antimicrob Agents Chemother 1993; 37: 407-413. (Pubitemid 23072581)
8. Rosenthal I M, Zhang M, Williams K N, et al. Daily dosing of rifapentine cures tuberculosis in three months or less in the murine model. PLoS Med 2007; 4: e344.
9. Cardona P J, Gordillo S, Diaz J, et al. Widespread bronchogenic dissemination makes DBA/2 mice more susceptible than C57BL/6 mice to experimental aerosol infection with Mycobacterium tuberculosis. Infect Immun 2003; 71: 5845-5854. (Pubitemid 37205638)
10. North R J. Mycobacterium tuberculosis is strikingly more virulent for mice when given via the respiratory than via the intravenous route. J Infect Dis 1995; 172: 1550-1553. (Pubitemid 3023469)
11. North R J, LaCourse R, Ryan L. Vaccinated mice remain more susceptible to Mycobacterium tuberculosis infection initiated via the respiratory route than via the intravenous route. Infect Immun 1999; 67: 2010-2012. (Pubitemid 29144429)
12. De Groote M A, Gilliland J C, Wells C L, et al. Comparative studies evaluating mouse models used for efficacy testing of experimental drugs against M. tuberculosis. Antimicrob Agents Chemother 2011; 55: 1237-1247.
13. Ibrahim M, Truffot-Pernot C, Andries K, et al. Sterilizing activity of R207910 (TMC207)-containing regimens in the murine model of tuberculosis. Am J Respir Crit Care Med 2009; 180: 553-557.
14. Nikonenko B V, Reddy V M, Protopopova M, et al. Activity of SQ641, a capuramycin analog, in a murine model of tuberculosis. Antimicrob Agents Chemother 2009; 53: 3138-3139.
15. Nuermberger E, Tyagi S, Tasneen R, et al. Powerful bactericidal and sterilizing activity of a regimen containing PA-824, moxifloxacin and pyrazinamide in a murine model of tuberculosis. Antimicrob Agents Chemother 2008; 52: 1522-1524. (Pubitemid 351522025)
16. Rosenthal I M, Zhang M, Almeida D, et al. Isoniazid or moxifloxacin in rifapentine-based regimens for experimental tuberculosis? Am J Respir Crit Care Med 2008; 178: 989-993.
17. Dhillon J, Dickinson J M, Sole K, et al. Preventive chemotherapy of tuberculosis in Cornell model mice with combinations of rifampin, isoniazid, and pyrazinamide. Antimicrob Agents Chemother 1996; 40: 552-555. (Pubitemid 26076566)